| Abuse and misuse of pregabalin and gabapentin: a systematic review update KE Evoy, S Sadrameli, J Contreras, JR Covvey, AM Peckham, ... Drugs 81, 125-156, 2021 | 171 | 2021 |
| Diagnosis and treatment of ADHD in the United States: Update by gender and race KA Fairman, AM Peckham, DA Sclar Journal of Attention Disorders 24 (1), 10-19, 2020 | 104 | 2020 |
| Gabapentin for off-label use: evidence-based or cause for concern? AM Peckham, KE Evoy, L Ochs, JR Covvey Substance Abuse: Research and Treatment 12, 1178221818801311, 2018 | 97 | 2018 |
| Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: an analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS) KE Evoy, JR Covvey, AM Peckham, L Ochs, KE Hultgren Research in Social and Administrative Pharmacy 15 (8), 953-958, 2019 | 91 | 2019 |
| Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance AM Peckham, MJ Ananickal, DA Sclar Risk management and healthcare policy, 109-116, 2018 | 91 | 2018 |
| All-cause and drug-related medical events associated with overuse of gabapentin and/or opioid medications: a retrospective cohort analysis of a commercially insured US population AM Peckham, KA Fairman, DA Sclar Drug Safety 41, 213-228, 2018 | 88 | 2018 |
| Prevalence of gabapentin abuse: comparison with agents with known abuse potential in a commercially insured US population AM Peckham, KA Fairman, DA Sclar Clinical Drug Investigation 37, 763-773, 2017 | 61 | 2017 |
| Drug–drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs KJ Goodlet, MT Zmarlicka, AM Peckham CNS spectrums 24 (3), 287-312, 2019 | 59 | 2019 |
| Predictors of gabapentin overuse with or without concomitant opioids in a commercially insured US population AM Peckham, KE Evoy, JR Covvey, L Ochs, KA Fairman, DA Sclar Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38 (4 …, 2018 | 53 | 2018 |
| Prevalence and characteristics of self-reported kratom use in a representative US general population sample JR Covvey, SM Vogel, AM Peckham, KE Evoy Journal of addictive diseases 38 (4), 506-513, 2020 | 45 | 2020 |
| Gabapentinoid pharmacology in the context of emerging misuse liability KE Evoy, AM Peckham, JR Covvey, KJ Tidgewell The Journal of Clinical Pharmacology 61, S89-S99, 2021 | 43 | 2021 |
| Opportunities to offer harm reduction to people who inject drugs during infectious disease encounters: narrative review AM Peckham, EH Young Open forum infectious diseases 7 (11), ofaa503, 2020 | 40 | 2020 |
| A survey of prescribers' attitudes, knowledge, comfort, and fear of consequences related to an opioid overdose education and naloxone distribution program AM Peckham, ME Niculete, H Steinberg, DL Boggs Journal of public health management and practice 24 (4), 310-317, 2018 | 38 | 2018 |
| Low dose initiation of buprenorphine: a narrative review and practical approach SM Cohen, MB Weimer, XA Levander, AM Peckham, JM Tetrault, ... Journal of addiction medicine, 2022 | 35 | 2022 |
| Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: a retrospective case series AM Peckham, LG Kehoe, JR Gray, SE Wakeman Journal of Substance Abuse Treatment 126, 108316, 2021 | 32 | 2021 |
| Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic AM Peckham, J Ball, MD Colvard, D Dadiomov, LG Hill, SD Nichols, ... American Journal of Health-System Pharmacy 78 (7), 613-618, 2021 | 29 | 2021 |
| Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 US states LG Hill, LJ Loera, SB Torrez, T Puzantian, KE Evoy, DJ Ventricelli, ... Drug and alcohol dependence 237, 109518, 2022 | 28 | 2022 |
| Delta-9-tetrahydrocannabinol and cannabidiol: Separating the chemicals from the “weed,” a pharmacodynamic discussion DL Boggs, A Peckham, AA Boggs, M Ranganathan Mental Health Clinician 6 (6), 277-284, 2016 | 25 | 2016 |
| Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample KE Evoy, JR Covvey, AM Peckham, KR Reveles International journal of clinical pharmacy, 1-10, 2021 | 24 | 2021 |
| Policies to mitigate nonmedical use of prescription medications: how should emerging evidence of gabapentin misuse be addressed? AM Peckham, KA Fairman, DA Sclar Expert Opinion on Drug Safety 17 (5), 519-523, 2018 | 24 | 2018 |
